Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings
| Autor: | Yuya Nakatani, Hisazumi Ikeda, Shinichiro Kuroshima, Hiroe Kakehashi, T. Ando, Izumi Asahina, Tokutarou Minamizato, Takako Kawasaki, Atsushi Kawakami |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Osteoporosis Teriparatide medicine Humans Adverse effect Aged Aged 80 and over Bisphosphonate-associated osteonecrosis of the jaw Bone Density Conservation Agents business.industry Bisphosphonate Middle Aged medicine.disease Surgery Treatment Outcome Otorhinolaryngology Bisphosphonate-Associated Osteonecrosis of the Jaw Female Oral Surgery Osteonecrosis of the jaw business medicine.drug Hormone |
| Zdroj: | International journal of oral and maxillofacial surgery. 44(12) |
| ISSN: | 1399-0020 |
| Popis: | Teriparatide is a synthetic polypeptide hormone that contains the 1-34 amino acid fragment of the recombinant human parathyroid hormone that stimulates bone formation. Currently, it is approved only for the treatment of osteoporosis. The outcomes of daily teriparatide injections for the treatment of bisphosphonate-related osteonecrosis of the jaw in 10 patients are reported here. Two of the 10 cases dropped out due to adverse events. Of the remaining eight cases, seven exhibited clinical improvement of the jaw-related symptoms of osteonecrosis and progression of the sequestration, while one case did not show improvement of the symptoms. Administration of teriparatide in patients with osteonecrosis of the jaw promotes bone formation and subsequent sequestration over a short period of time. These results suggest that adjunctive teriparatide therapy is a viable and effective option for treating osteonecrosis of the jaw. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect